sk&f-38393 has been researched along with Movement Disorders in 7 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " SCH 23390 (a selective D1 antagonist) and raclopride (a selective D2 antagonist) induced identical syndromes consisting of dystonia and oral dyskinesia." | 3.67 | Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. ( Gerlach, J; Kistrup, K, 1987) |
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomiyama, K | 2 |
| O'Tuathaigh, CM | 1 |
| O'Sullivan, GJ | 1 |
| Kinsella, A | 2 |
| Lai, D | 1 |
| Harvey, RP | 1 |
| Tighe, O | 1 |
| Croke, DT | 1 |
| Koshikawa, N | 2 |
| Waddington, JL | 2 |
| Kim, HA | 1 |
| Ehrlich, ME | 1 |
| Schütz, G | 1 |
| Lawrence, AJ | 1 |
| Drago, J | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Olsson, M | 1 |
| Nikkhah, G | 1 |
| Bentlage, C | 1 |
| Björklund, A | 1 |
| Kistrup, K | 1 |
| Gerlach, J | 1 |
| Barone, P | 1 |
| Bankiewicz, KS | 1 |
| Corsini, GU | 1 |
| Kopin, IJ | 1 |
| Chase, TN | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
7 other studies available for sk&f-38393 and Movement Disorders
| Article | Year |
|---|---|
Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Jaw; Mice; M | 2009 |
Phenotypic disruption to orofacial movement topography in conditional mutants with generalized CamKIIa/Cre D1Tox versus striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Calcium-Calmodulin-Dependent Pr | 2011 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 1995 |
Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Benzazepi | 1987 |
Dopaminergic mechanisms in hemiparkinsonian monkeys.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Biomechanical Phe | 1987 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |